Article Finder
Browse our vast collection of articles. Simply select a category on the left and find a list of related articles on the right.
Article Category
Article Title
- Giving Up the Guns When a Family Member Has Alzheimer’s
- Care Management Program Is Reducing Need for Anti-anxiety Medication and Visits to the Hospital/Emergency Room
- Talking to a Loved One With Alzheimer’s
- 10 Powerful Ways to Commemorate Alzheimer’s Awareness Month
- Making the Most of Mealtimes for People With Alzheimer’s
- Family Members Provide 100 Hours a Month of Unpaid Care for Alzheimer’s
- Alzheimer’s Caregivers Should Be Screened for Depression
- Alzheimer’s Care Costs Far More Than Heart Disease or Cancer Care
- Obesity at Midlife May Speed Alzheimer’s Onset
- Hello from my mom
- FOR MORE ARTICLES CLICK HERE
- Heart Rhythm Disorder, A-Fib, Tied to Dementia Risk
- Daytime Sleepiness Tied to Alzheimer’s Brain Changes
- Stress May Affect Memory and Brain Size
- Memory and Thinking Skills May Wane in Winter Months
- High Blood Pressure at Age 50 Tied to Dementia Later in Life
- High Fat, High Sugar Diet Tied to Alzheimer’s Brain Changes
- Kidney Dialysis Patients at High Risk of Alzheimer’s Disease
- Daytime Sleepiness May Be Early Warning Sign of Alzheimer’s
- Alzheimer’s Disease Increases the Risk of Falls
- High Blood Sugar Tied to Memory Decline
- FOR MORE ARTICLES CLICK HERE
- Experimental Drug, Fails to Benefit Alzheimer’s Patients
- New Drug Shows Promise for Alzheimer’s
- Pain Relievers Present Special Hazards in People With Alzheimer’s Disease
- Care Management Program Is Reducing Need for Anti-anxiety Medication and Visits to the Hospital/Emergency Room
- Music May Ease the Anxiety of Alzheimer’s
- Experimental Alzheimer’s Drug, Intepirdine, Disappoints in Study
- An Eye Scan for Alzheimer’s?
- Drug to treat Alzheimer’s is Ranked Highest
- Patients Often Fail to Adhere to Alzheimer’s Drug Schedules
- Could Treatments for Diabetes Help Treat Alzheimer’s?
- FOR MORE ARTICLES CLICK HERE
- To Drive or Not to Drive? Questions to Ask
- Exercise May Prevent Falls in Those with Alzheimer’s Disease
- The Driving and Car Key Dilemma of Alzheimer’s Disease
- Healthier Heart, Healthier Brain
- 2 Hours a Week of Exercise Can Boost Brain Health
- ‘Exergames,’ Which Combine Exercise and Games, May Benefit Brain Health
- Eat Fish, Fruit, Vegetables and Nuts for Brain Health
- Beet Compound Shows Promise Against Alzheimer’s
- A Single Night of Not Sleeping Tied to Alzheimer’s Brain Changes
- Should Alzheimer’s Patients Drink Coffee?
- FOR MORE ARTICLES CLICK HERE
- Some 44 Million People Have Alzheimer’s Worldwide
- Nearly 14 Million Americans Will Have Alzheimer’s Disease by 2060
- Alzheimer’s Rates Could Double in Coming Decades
- Combining Care Program With Medication Reduces Alzheimer’s Symptoms By 750%
- Fisher Center Scientists make two new Significant Discoveries in the battle against Alzheimer’s
- Dementia Rates Are Slowing, but Alzheimer’s Cases Continue to Rise
- Fisher Center Scientists Create a Novel Imaging Technology Allowing the 3D Visualization of Brain Defects That Cause Alzheimer’s Disease
- Negative Beliefs About Aging Could Prime the Brain for Alzheimer’s
- Recognizing Faces Is a Challenge for Those With Alzheimer’s
- Fisher Center Scientists Discover Pathway That may Lead to Alzheimer’s Disease
- FOR MORE ARTICLES CLICK HERE
- Fisher Center For Alzheimer’s Research Foundation Wins Fall 2018 Digital Health Awards®
- Fisher Center for Alzheimer’s Research Foundation Earns Gold Seal of Transparency from GuideStar
- The Fisher Center for Alzheimer’s Research Foundation Earns Coveted 4-Star Rating from Charity Navigator for the 7th Consecutive Year
- Hear Kent Karosen, President and CEO of the Fisher Center for Alzheimer’s Research Foundation, describe his new book and the power of art therapy
- Fisher Center Scientists link a Mutation That Protects Against the Development of Alzheimer’s Disease
- Newly Inducted Into the Basketball Hall of Fame, Shaquille O’Neal, Joins the Fisher Center for Alzheimer’s Research Foundation to Raise Funds for Groundbreaking Research in the Quest for a Cure
- Pat Summitt, legendary women’s basketball coach, dies at 64
- Celebrating the life of Nancy Reagan for her Impact on the Fight to end Alzheimer’s
- WRNN Interview
- Fisher Center’s 20th Anniversary Celebration and recent activities
- FOR MORE ARTICLES CLICK HERE
Two-Drug Combo May Ease the Agitation of Alzheimer’s
Agitation is a common symptom of Alzheimer’s disease, and safe and effective treatments for the condition are lacking. Now, a preliminary study has found that a combination of two drugs may be relatively safe and effective in easing the agitation of Alzheimer’s.
The findings are important since behavioral problems like agitation and aggression are a major source of distress for patients and caregivers, and are often the reason why people with Alzheimer’s are moved from the home into a nursing home. They can also hasten the progression to severe dementia and death. Better treatments are needed for such behaviors, which affect more than 90 percent of people with Alzheimer’s.
The study looked at two drugs: dextromethorphan, a cough suppressant, and quinidine, a drug for irregular heart rhythms. The combination is currently used to treat a brain condition unrelated to Alzheimer’s that causes emotional outbursts.
For the study, researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas divided about 200 men and women with probable Alzheimer’s into two groups. Half got the drug combo for five weeks, while the others got a placebo dummy pill.
After five weeks of treatment, those taking the drug combo had fewer periods of agitation, and the agitation was less severe.
After 10 weeks of treatment, 45 percent of those who received the drugs showed improvements in agitation, compared with 21 percent of those receiving a placebo. The drugs did not appear to improve cognition or lead to undue sedation. The findings appeared in JAMA, from the American Medical Association.
Scientists are not sure why these drugs have a calming effect, though they seem to alter levels of brain chemicals like glutamate, serotonin and norepinephrine that affect emotions and may also play a role in Alzheimer’s disease. The drugs may also have pain-relieving effects.
Non-drug treatments are recommended as the first line of treatment for behavioral problems from Alzheimer’s. There is no substitute for good supportive care and knowledgeable, compassionate caregivers. Having people with Alzheimer’s spend at least 60 minutes a week in activities that they enjoy, for example, has been shown to have calming benefits. Music, art and pet therapy may also help to ease stress and anxiety, although none of these treatments is a cure. Regular medical and dental care is also essential to rule out pain and other health problems that may be increasing agitation.
Current drugs to ease the memory and thinking problems of Alzheimer’s, such as Aricept, are no more effective than a placebo in easing symptoms like agitation, studies have shown. To treat behavioral problems, doctors often prescribe antipsychotic drugs, but they can have severe side effects, including an increased risk of heart attacks and strokes, and can accelerate memory decline. They may also cause sedation and are often not effective in reducing agitation. The antidepressant drug citalopram (brand name Celexa) has also shown some benefits for easing the agitation of Alzheimer’s. Similar antidepressants, called selective serotonin reuptake inhibitors (SSRIs), may also successfully treat depression and anxiety.
The combination of quinidine and dextromethorphan seemed to be safer than current antipsychotic drugs, with fewer side effects. Side effects for the drug combo included an increased risk of falls, stomach upset and urinary tract infections.
In an editorial accompanying the study, experts called the results “encouraging.” More research is needed to confirm the findings, but they suggest that the combination might be a useful tool for easing agitation in people with Alzheimer’s.
“Pending further evidence, there is a reasonably strong case to prioritize dextromethorphan-quinidine as an off-label treatment for agitation, possibly as a safer alternative to atypical antipsychotics,” wrote the editorial authors, from King’s College London.
By ALZinfo.org, The Alzheimer’s Information Site. Reviewed by William J. Netzer, Ph.D., Fisher Center for Alzheimer’s Research Foundation at The Rockefeller University.
Sources: Jeffrey L. Cummings MD, ScD, Constantine G. Lyketsos MD, MHS, Elaine R. Peskind MD, et al: “Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia.” JAMA Sept. 22-29, 2015.
Clive Ballard MD, Samantha Sharp, BSc, Anne Corbett, PhD, et al: “Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia” (editorial). JAMA Sept. 22-29, 2015.
